Hemoglobinopathies: all 100 studies

Page 1 of 1. Open to participants first (29), then studies with results posted, then the rest; newest registration first within each.

• A Clinical Exploratory Study of YOLT-204 in the Treatment of HemoglobinopathiesNot yet recruitingNCT07774351Not applicable
• Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant DiseasesNot yet recruitingNCT07660783Phase 2
• A Long-term Follow-up Study in Patients Who Received BEAM-101RecruitingNCT07373639
• Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease EndotypeRecruitingNCT07282210Phase 2
• The HOPE Biobank Resource (BMT CTN 2402 HOPE)RecruitingNCT07227155
• Integrative Diagnosis for SCD and Other RADsRecruitingNCT07206095
• YOLT-204 in Patients With HemoglobinopathiesNot yet recruitingNCT07190001Early Phase 1
• A Phase I Study of SNH-119014 in Healthy VolunteersRecruitingNCT07087262Phase 1
• PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]RecruitingNCT06923111
• Allo HSCT for High Risk HemoglobinopathiesRecruitingNCT06872333Phase 2
• Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCTRecruitingNCT06839456Phase 1/2
• Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.RecruitingNCT06655662Phase 1
• Long Term Follow-Up Study for Individuals With Hemoglobin Disorders After Hematopoietic Cell Transplant or Gene TherapyRecruitingNCT06646640
• A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301Enrolling by invitationNCT06363760
• Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin LabelingRecruitingNCT06313398Early Phase 1
• RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)RecruitingNCT06213402
• Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring DiseaseRecruitingNCT06107400Early Phase 1
• Study of the Role of Genetic Modifiers in HemoglobinopathiesRecruitingNCT05799118
• Atrial Fibrillation in Beta-ThalassemiaRecruitingNCT05508932
• Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell DiseaseRecruitingNCT05477563Phase 3
• STUDY INCIDENCE AND CHARACTERISTICS OF MALIGNANT NEOPLASIES IN PATIENTS WITH HEMOGLOBINOPATHY FOLLOWED IN ITALYRecruitingNCT05286138
• Observational Study for Patients With Hemoglobinopathies and Rare Inherited Anemia and Covid 19RecruitingNCT04746066
• Discarded Bone Marrow for Hematology ResearchRecruitingNCT04671212
• Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant DisordersRecruitingNCT04644016Phase 2
• TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in ChildrenRecruitingNCT04356469Phase 2
• A Long-term Follow-up Study in Participants Who Received CTX001Enrolling by invitationNCT04208529Phase 3
• Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant DisordersRecruitingNCT03128996Phase 1/2
• Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)RecruitingNCT01666080Not applicable
• Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant DiseasesRecruitingNCT00920972Phase 1/2
• Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 DepletionActive, not recruitingNCT05236764Not applicableResults posted
• A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy VolunteersCompletedNCT03926819Phase 1Results posted
• Pharmacokinetics of Oral Hydroxyurea SolutionCompletedNCT03763656Phase 1/2Results posted
• A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell DiseaseCompletedNCT03745287Phase 2/3Results posted
• Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical StudyTerminatedNCT03733249Phase 1/2Results posted
• Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell AnemiaCompletedNCT02961218Phase 2Results posted
• Is Iron Deficiency the Cause of Anemia Among Women in Cambodia?CompletedNCT02481375Not applicableResults posted
• Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant DiseasesTerminatedNCT02231710Phase 1Results posted
• Feasibility Study of Unfractionated Heparin in Acute Chest SyndromeTerminatedNCT02098993Phase 2Results posted
• Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell TransplantTerminatedNCT02065869Phase 1/2Results posted
• Non-Myeloablative Conditioning and Bone Marrow TransplantationActive, not recruitingNCT01850108Not applicableResults posted
• Treatment of Sickle Cell Anemia With Stem Cell TransplantTerminatedNCT01350232Not applicableResults posted
• Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant DisordersCompletedNCT01050855Phase 2Results posted
• T-cell Depleted Alternative Donor TransplantationTerminatedNCT00968864Phase 2Results posted
• Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited DisordersCompletedNCT00919503Phase 2Results posted
• Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant DisordersCompletedNCT00744692Phase 1Results posted
• A Pilot Study of HSCT for Patients With High-risk Hemoglobinopathy Using a Nonmyeloablative Preparative RegimenCompletedNCT00427661Not applicableResults posted
• Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With HemoglobinopathiesCompletedNCT00153985Phase 2Results posted
• Prevalence of Abnormal Haemoglobin Variants in Metropolitan Chattogram, BangladeshCompletedNCT07305181
• Prevalence of Hemoglobinopathies Associated With Significant Hb Variants in the Chattogram Region of BangladeshCompletedNCT07207551
• Prevalence and Hematological Characteristics of HemoglobinopathiesCompletedNCT07180836
• ERN-EuroBloodNet Registry on Patients with Rare Red Blood Cell Defects and COVID-19CompletedNCT06831799
• Long Term Beta Thalassemia Treatment: Findings From The Extension PeriodActive, not recruitingNCT06490601Phase 2
• A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)CompletedNCT06144749Phase 2
• A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in IndiaActive, not recruitingNCT05891249Phase 4
• EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)Active, not recruitingNCT05444894Phase 1/2
• Hemoglobinopathy Nursing Program and Pediatric Nursing StudentsCompletedNCT05389891Not applicable
• Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)Active, not recruitingNCT05356195Phase 3
• Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)Active, not recruitingNCT05329649Phase 3
• A Study of Etavopivat in Patients With Thalassemia or Sickle Cell DiseaseCompletedNCT04987489Phase 2
• A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)Active, not recruitingNCT04853576Phase 1/2
• Transcranial Doppler in Children With HemoglobinopathiesStatus unknownNCT04798157Not applicable
• A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)Active, not recruitingNCT04624659Phase 3
• Pediatrics HOT COVID-19 Database in NY TristateCompletedNCT04445402
• Screening for Hemoglobinopathies in Pregnant WomenCompletedNCT04029142
• A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-ThalassemiaCompletedNCT03655678Phase 2/3
• Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant PatientsCompletedNCT03609840
• Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant PatientsCompletedNCT03609827
• Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)CompletedNCT03609814
• A Blood Stem Cell Transplant for Sickle Cell DiseaseActive, not recruitingNCT03249831Phase 1
• Hepatitis C Virus Infection in Patients With HemoglobinopathiesCompletedNCT03149289
• Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology GroupWithdrawnNCT03141398
• In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)TerminatedNCT02986698Phase 1
• Fetal Hemoglobin Induction Treatment MetforminCompletedNCT02981329Early Phase 1
• Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant DiseasesCompletedNCT02349906Phase 2
• Lucky Iron Fish Home Fortification of IronCompletedNCT02341586Not applicable
• Gene Transfer for Patients With Sickle Cell DiseaseTerminatedNCT02186418Phase 1/2
• CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell TransplantActive, not recruitingNCT02061800Phase 1/2
• CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell TransplantationActive, not recruitingNCT01966367Phase 1/2
• Study of Fludarabine Drug Exposure in Pediatric Bone Marrow TransplantationCompletedNCT01316549
• Malaria Surveillance in Rakai, UgandaCompletedNCT01265407
• MACS Study - Microparticles and Coagulation in Sickle Cell DiseaseStatus unknownNCT01242878
• Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell TransplantNo longer availableNCT01200017
• Interferon and Ribavirin Treatment in Patients With HemoglobinopathiesStatus unknownNCT00887081Phase 4
• Phase I/II Pilot Study of Mixed Chimerism to Treat HemoglobinopathiesCompletedNCT00777231Phase 1/2
• Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron OverloadCompletedNCT00673608Phase 4
• Innate and Acquired Resistance to Plasmodium Falciparum Malaria in MaliCompletedNCT00669084
• Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb HomozygousCompletedNCT00481260
• Collection of Blood From Persons With Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria ResearchCompletedNCT00277849
• Reduced Intensity Transplant Using Extracorporeal PhotopheresisCompletedNCT00179790Phase 1/2
• Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid PhenotypesTerminatedNCT00102245
• Bone Marrow Transplant From Related Donor for Patients With High Risk HemoglobinopathiesTerminatedNCT00040469Phase 2
• Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk HemoglobinopathiesTerminatedNCT00040417Phase 2
• Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or ThalassemiaTerminatedNCT00034528Phase 2
• Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)CompletedNCT00001958Phase 2
• Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG)CompletedNCT00000602Phase 2
• Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional HemochromatosisCompletedNCT00000595Phase 2
• Stroke Prevention in Sickle Cell Anemia (STOP 1)CompletedNCT00000592Phase 3
• Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl HydrazoneCompletedNCT00000588Phase 2
• Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)CompletedNCT00000586Phase 3
• Penicillin Prophylaxis in Sickle Cell Disease (PROPS)CompletedNCT00000585Phase 3

← Hemoglobinopathies overview